Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

3.100 -0.070 (-2.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings
 
Via Benzinga
Earnings Scheduled For June 17, 2025
 
Via Benzinga
Insights into VistaGen Therapeutics's Upcoming Earnings
 
Via Benzinga
Earnings Scheduled For February 13, 2025
 
Via Benzinga
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
Recap: Vistagen Therapeutics Q3 Earnings
 
Via Benzinga
VistaGen Therapeutics's Earnings: A Preview
 
Via Benzinga
VistaGen Therapeutics Earnings Preview
 
Via Benzinga
3 Stocks Under $15 That Could Make You a Millionaire
Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying. 
Via InvestorPlace
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
Though volatility remains high, these penny stocks promise significant returns, especially in this high-interest rate economic climate. 
Via InvestorPlace
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
The internet and forums such as Reddit, are rife with misinformation about stock prospects. However, these three might have potential. 
Via InvestorPlace
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
Explore three stocks under $10 in electronic equipment and instruments, technology hardware, storage and peripherals, and biotechnology. 
Via InvestorPlace
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
Learn the potency of lesser-known stocks and explore their fundamental edge in technology distribution, food retail, and biotechnology. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
3 Penny Stocks to Buy for the Next Bull Run: February 2024
As the market pivots in 2024, dive into the dynamic world of penny stocks, revealing the top choices for February's exhilarating bull run. 
Via InvestorPlace
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets. 
Via InvestorPlace
Topics Economy
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety... 
Via Benzinga
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder... 
Via Benzinga
Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price... 
Via Benzinga
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.